Jude Onyia's most recent trade in Neurocrine Biosciences, Inc. was a trade of 3,110 Common Stock done . Disclosure was reported to the exchange on Feb. 20, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 20 Feb 2026 | 3,110 | 25,670 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2026 | 55,119 | 55,119 | - | - | Stock Option | |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2026 | 19,935 | 39,535 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 124.12 per share. | 12 Feb 2026 | 10,755 | 28,780 (0%) | 0% | 124.1 | 1,334,911 | Common Stock |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2026 | 9,669 | 9,669 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 2,717 | 21,066 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 2,717 | 2,717 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 2,690 | 5,380 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 2,690 | 19,801 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 2,560 | 7,681 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2026 | 2,560 | 18,537 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 124.12 per share. | 12 Feb 2026 | 1,466 | 19,600 (0%) | 0% | 124.1 | 181,960 | Common Stock |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 124.12 per share. | 12 Feb 2026 | 1,452 | 18,349 (0%) | 0% | 124.1 | 180,222 | Common Stock |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 123.10 per share. | 12 Feb 2026 | 1,426 | 17,111 (0%) | 0% | 123.1 | 175,541 | Common Stock |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2026 | 238 | 0 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2026 | 238 | 16,119 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 136.06 per share. | 31 Jan 2026 | 142 | 15,977 (0%) | 0% | 136.1 | 19,321 | Common Stock |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Nov 2025 | 4,426 | 0 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Nov 2025 | 4,426 | 18,129 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 152.16 per share. | 29 Nov 2025 | 2,248 | 15,881 (0%) | 0% | 152.2 | 342,056 | Common Stock |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 03 Sep 2025 | 1,470 | 13,703 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 05 Aug 2025 | 3,116 | 15,173 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 84.74 per share. | 09 Jul 2025 | 59,819 | 78,108 (0%) | 0% | 84.7 | 5,069,062 | Common Stock |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jul 2025 | 59,819 | 35,268 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 130.46 per share. | 09 Jul 2025 | 59,819 | 18,289 (0%) | 0% | 130.5 | 7,803,688 | Common Stock |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jul 2025 | 20,362 | 95,087 | - | - | Non-Qualified Stock Option | |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 130.13 per share. | 02 Jul 2025 | 20,362 | 18,289 (0%) | 0% | 130.1 | 2,649,738 | Common Stock |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 84.74 per share. | 02 Jul 2025 | 20,362 | 38,651 (0%) | 0% | 84.7 | 1,725,476 | Common Stock |
| Voyager Therapeutics Inc | Jude Onyia | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 24,000 | 24,000 | - | - | Stock Option (Right to Buy) | |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 54,645 | 54,645 | - | - | Stock Option | |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 10,241 | 10,241 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 2,717 | 18,278 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 2,717 | 5,434 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 2,690 | 19,536 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 2,690 | 8,070 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 116.75 per share. | 12 Feb 2025 | 1,447 | 18,089 (0%) | 0% | 116.7 | 168,933 | Common Stock |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 116.83 per share. | 12 Feb 2025 | 1,432 | 16,846 (0%) | 0% | 116.8 | 167,306 | Common Stock |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 238 | 238 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 238 | 15,687 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 152.97 per share. | 31 Jan 2025 | 126 | 15,561 (0%) | 0% | 153.0 | 19,274 | Common Stock |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Nov 2024 | 4,426 | 4,426 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences Inc | Onyia Jude | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Nov 2024 | 4,426 | 17,780 (0%) | 0% | 0 | Common Stock | |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 126.29 per share. | 29 Nov 2024 | 2,331 | 15,449 (0%) | 0% | 126.3 | 294,373 | Common Stock |
| Voyager Therapeutics Inc | Jude Onyia | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 24,000 | 24,000 | - | - | Stock Option (Right to Buy) | |
| Neurocrine Biosciences Inc | Onyia Jude | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 54,069 | 54,069 | - | - | Stock Option | |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 10,760 | 10,760 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences Inc | Onyia Jude | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 132.94 per share. | 13 Feb 2024 | 1,432 | 13,128 (0%) | 0% | 132.9 | 190,371 | Common Stock |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 141.94 per share. | 31 Jan 2024 | 126 | 11,843 (0%) | 0% | 141.9 | 17,884 | Common Stock |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 107.37 per share. | 21 Aug 2023 | 3,198 | 9,638 (0%) | 0% | 107.4 | 343,368 | Common Stock |
| Voyager Therapeutics Inc | Jude Onyia | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 22,000 | 22,000 | - | - | Stock Option (Right to Buy) | |
| Voyager Therapeutics Inc | Jude Onyia | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 44,000 | 44,000 | - | - | Stock Option (Right to Buy) | |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 67,541 | 67,541 | - | - | Stock Option | |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 10,868 | 10,868 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 102.30 per share. | 07 Feb 2023 | 4,508 | 6,525 (0%) | 0% | 102.3 | 461,166 | Common Stock |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 108.48 per share. | 31 Jan 2023 | 126 | 2,477 (0%) | 0% | 108.5 | 13,668 | Common Stock |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 121.90 per share. | 29 Nov 2022 | 2,331 | 2,366 (0%) | 0% | 121.9 | 284,160 | Common Stock |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 6,464 | 6,464 | - | - | Stock Option | |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 950 | 950 | - | - | Restricted Stock Unit | |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Nov 2021 | 120,169 | 120,169 | - | - | Stock Option | |
| Neurocrine Biosciences Inc | Jude Onyia | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Nov 2021 | 17,702 | 17,702 | - | - | Restricted Stock Unit |